Table 2.
Diagnostic value of autoantibodies to CENPF, HSP60 and IMP-2 for HCC or early-HCC.a
| aAb | Case number HCC/LC/CH/HC |
AUC value | 95% CI | Cutoff value | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|---|
| CENPF aAb | ||||||||
| HCC | 291/105/83/200 | 0.816 | 0.785 to 0.844 | > 1152 | 75.3 | 73.7 | 68.2 | 79.9 |
| Early-HCC | 106/105/83/200 | 0.826 | 0.790 to 0.859 | > 1152 | 76.2 | 73.7 | 44.0 | 92.0 |
| HSP60 aAb | ||||||||
| HCC | 291/91/85/201 | 0.750 | 0.715 to 0.783 | > 3712 | 77.7 | 62.2 | 61.4 | 78.3 |
| Early-HCC | 106/91/85/201 | 0.764 | 0.723 to 0.801 | > 3712 | 78.1 | 62.2 | 36.6 | 91.1 |
| IMP-2 aAb | ||||||||
| HCC | 92/99/91/65 | 0.708 | 0.656 to 0.756 | > 640 | 69.2 | 65.1 | 37.8 | 87.4 |
| Early-HCC | 38/99/91/65 | 0.796 | 0.746 to 0.841 | > 640 | 81.6 | 65.1 | 25.8 | 96.0 |
a
Control: liver cirrhosis + chronic hepatitis + healthy controls; aAb: autoantibody; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healthy controls.